uPAR promotes the resistance to tamoxifen in breast cancer by activated ERK1/2 activity (22), and confers the resistance to gefitinib in non-small-cell lung cancer through activated EGFR/pAKT/survivin signal pathway (23). This evidence concerns the gene EGFR and breast carcinoma.